NEW YORK – Mission Bio and Sequanta Technologies said on Thursday that they have entered into a strategic partnership to provide single-cell sequencing services to customers in mainland China.
Under the terms of their partnership, Sequanta will provide access to Mission Bio's Tapestri single-cell platform on a fee-for-service basis.
"We are excited to work with Sequanta, especially given their synergies with academic cancer centers, and their expertise in cell and gene therapy services," said Yan Zhang, CEO of Mission Bio. "Through our partnership with Sequanta, we are introducing key multiomics methods to China that can power the next wave of critical discoveries."
Financial and other terms of the deal were not disclosed.
Mission Bio, based in South San Francisco, California, offers single-cell DNA and cell surface protein analysis through Tapestri. In January, the firm signed a distribution deal for the Netherlands, Belgium, and Luxembourg with Bioké.
Sequanta Technologies is a Shanghai-based research and clinical services provider with a focus on genomics and proteomics.